Sunitinib Shows Good Response in Treatment of Refractory Thymic Carcinoma
the Cancer Therapy Advisor take:
Sunitinib is a tyrosine kinase inhibitor capable of inhibiting tumor growth and slowing down the progression of metastatic cancers.
Investigators wished to determine the potential activity of sunitinib for the treatment of advanced thymic epithelial tumors, including thymoma and thymic carcinoma, which are rare and aggressive forms of tumors on the outside surface of the thymus gland.
Investigators conducted an open-label phase II study, evaluating patients with chemotherapy-refractory thymic epithelial tumors. There were 41 patients enrolled in the study, in which 25 patients had thymic carcinoma and 16 patients had thymoma carcinoma.
All participants received sunitinib 50mg oral tablets taken once daily in 6-week cycles until further progression or toxic adverse effects occurred. The primary endpoint of the study was to see best tumor response at any point, assessed by the investigators.
Of the 23 patients with thymic carcinoma, 21 patients (91%) achieved disease control, of which six (26%, 90% CI 12.1–45.3, 95% CI 10.2–48.4) had partial responses and 15 (65%, 95% CI 42.7–83.6) achieved stable disease. Of the 16 patients with thymoma carcinoma, 13 patients (81%) achieved disease control, of which one (6%, 95% CI 0.2–30.2) had a partial response and 12 (75%, 47.6–92.7) had stable disease.
The results of the study demonstrated that sunitinib is an effective treatment for thymic carcinoma; however, investigators conclude that further studies need to be conducted to identify sunitinib’s potential biomarkers of activity.
Potential activity of sunitinib for the treatment of advanced thymic epithelial tumors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models